IShares Nasdaq Biotechnology ETF Profit Margin 1970-1969 | IBB

Current and historical gross margin, operating margin and net profit margin for IShares Nasdaq Biotechnology ETF (IBB) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. IShares Nasdaq Biotechnology ETF net profit margin as of December 31, 1969 is 0%.
IShares Nasdaq Biotechnology ETF Annual Profit Margins
IShares Nasdaq Biotechnology ETF Quarterly Profit Margins
Sector Industry Market Cap Revenue
Finance Finance - Publicly Traded Investment Trusts $7.087B $0.000B
The ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.
Stock Name Country Market Cap PE Ratio
Sea (SE) Singapore $10.138B 0.00
Adams Diversified Equity Fund (ADX) United States $1.746B 0.00
Lifestyle Holdings (LFSYY) Hong Kong, SAR China $1.622B 0.00
Compass Diversified Holdings (CODI) United States $1.343B 16.36
Taiwan Fund (TWN) United States $0.160B 0.00
Equus Total Return (EQS) United States $0.021B 0.00
GSV Capital Corp (SSSS) United States $0.000B 0.00